Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
Bradley J. Monk(Florida Cancer Specialists & Research Institute), Jyoti Mayadev(University of California San Diego Medical Center), Takafumi Toita(Okinawa Prefectural Chubu Hospital), Francisco Javier Ramírez Godinez(Hospital Civil de Guadalajara), Umesh Mahantshetty(Homi Bhabha National Institute), Guihao Ke(Fudan University Shanghai Cancer Center), Daisuke Aoki(International University of Health and Welfare), Yulia Kreynina(Privolzhsky Research Medical University), Felipe Rey(Dirección de Investigación y Desarrollo), Juan Carlos Vázquez Limón(Harbin Medical University), Ana T. Nunes(AstraZeneca (United States)), Masaki Mandai(Kyoto University), R. Tarnawski(The Maria Sklodowska-Curie National Research Institute of Oncology), Natalia Valdiviezo(Instituto Nacional de Enfermedades Neoplásicas), Ronnie Shapira‐Frommer(Sheba Medical Center), Hannah Dry(AstraZeneca (United States)), Jung‐Yun Lee(Yonsei University), Maria Del Pilar Estevez-Diz(International Organization for Migration), Yi Rong(University of California, Davis), Sewanti Limaye(Sir H.N. Reliance Foundation Hospital and Research Centre), Christina Oppermann Kussler(Hospital Mãe de Deus), Raymond Sulay(Perpetual Succour Hospital), Xiaohua Wu(Fudan University Shanghai Cancer Center), Manuel Leiva(Universidad Ricardo Palma), Wen‐Fang Cheng(Harbin Medical University), Szilvia Varga(National Institute of Oncology), Andrew R. Lloyd(Oregon Health & Science University), Qi Zhou(Chongqing University), Sophie Wildsmith(AstraZeneca (United Kingdom))
Cited by 214
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k